InvestorsHub Logo
Followers 30
Posts 2793
Boards Moderated 0
Alias Born 12/05/2021

Re: Kam8 post# 690198

Friday, 05/10/2024 11:20:01 AM

Friday, May 10, 2024 11:20:01 AM

Post# of 693492

Dear dennisdave, are you guessing we would see "BinGO B...O" by Christmas this year ??



Hi Kam8
I am expecting the announcement of a licensing deal with a large pharma for the right to sell DCVAXL right after UK approval.
As soon as it is public that NWBO has received approval in the UK they will be overwhelmed by dozens of phone calls from Medical Doctors, patients, and caregivers for information on how to get DCVAXL treatment. NWBO and Advent lack any form of infrastructure whatsoever to sell, support, market and instruct others about DCVAXL. More important NWBO keeps saying that they lack the infrastructure to sell, support, market and instruct others about DCVAXL in their 10K/Q. With a financial influx of what I think will be around $300 million in July/August plus UK approval, the stock price will fly. Thats 1

2. NWBO will then uplist to NASDAQ or another major stock exchange. I dont think that a R/S will be necessary
3. NWBO will NOT start conducting any other joint trial with a large pharma. NWBO lacks any sort of infrastructure to conduct medical trials with a large pharma.
They dont any medical trial experts or scientists employed to conduct any sort of meaningful scientific research (and no UCLA staff do not count as NWBO employees) they dont have any accounting, CFO, trial patient spokesperson and most importantly the most important person (NWBO's CTO dr Bosch) lives 5,500 miles to the East of where he should be front and center to lead the troops in any joint trial.
4. NWBO management is old, tired and worn out.
5. The last person hired at the BOD Mr. Pat Sarma has ZERO experience and can contribute NOTHING to building NWBO into some sort of cancer treatment powerhouse the zealots dream about. Why not hire an experienced medical trial for cancer MD? Pat Sarma is an total nobody
6. 90% of all non-revenue biotech with an approved drug are bought
7. Linda Powers love and energy is into building CDMO's She absolutely detests leading a biotech. As we can see a lot of NWBO's energy and effort over the last 10 years have been aimed at building Advent and before that Cognaote. Both are non-NWBO subsidiaries and both are not listed as something that Powers loves. Powers HATES shareholders she has to be accountable for.

So all in all I'm 95% confident NWBO will be bought. I think before the end of this year December or Q1 next year after the stock price has adjusted accordingly.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News